CD30
CD30 is a protein on the malignant Reed-Sternberg cells of Hodgkin lymphoma and on some T-cell lymphomas, and the address for the ADC brentuximab vedotin.
TNF-receptor family member expressed on activated lymphocytes and near-universally on Hodgkin Reed-Sternberg cells, anaplastic large-cell lymphoma, and subsets of peripheral T-cell lymphoma and DLBCL. Brentuximab vedotin (2011) validated it; CD30 CAR-T (phase 1/2, ~60-70% ORR in relapsed Hodgkin) and CD30 bispecifics are in trials. Expression level does not predict brentuximab response well.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CD30 is a protein on the malignant Reed-Sternberg cells of Hodgkin lymphoma and on some T-cell lymphomas, and the address for the ADC brentuximab vedotin.
- 1 · What it is
CD30 is a protein on the malignant Reed-Sternberg cells of Hodgkin lymphoma and on some T-cell lymphomas, and the address for the ADC brentuximab vedotin.
- 2 · What goes wrong in cancer
Signals via TRAF proteins to NF-κB; shed soluble CD30 is a serum marker. Sparse normal expression outside activated T and B cells.
- 3 · How drugs use it
No product in this corpus aims at CD30 yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Biology
Signals via TRAF proteins to NF-κB; shed soluble CD30 is a serum marker. Sparse normal expression outside activated T and B cells.
- Classical Hodgkin lymphoma (~100%)
- Anaplastic large-cell lymphoma
- Peripheral T-cell lymphoma (subset)
- Primary mediastinal B-cell lymphoma
- Embryonal carcinoma
S1826 moved checkpoint blockade into first-line Hodgkin lymphoma and made N-AVD a preferred regimen for advanced disease in patients from adolescence to older age, while removing radiotherapy for most. It also showed the value of a single trial spanning paediatric and adult groups. Longer follow-up is needed for overall survival and late immune effects in young patients.
ECHELON-1 made a targeted antibody-drug conjugate part of first-line Hodgkin therapy and eventually showed that this saves lives, not just relapses. It set the reference arm against which nivolumab-AVD (SWOG S1826) and BrECADD (HD21) were later compared. Neuropathy is the main price and needs proactive dose modification.
Latest papers
topQuery for this target: (TITLE:"CD30" OR ABSTRACT:"CD30" OR TITLE:"TNFRSF8" OR ABSTRACT:"TNFRSF8") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD30, not a curated reading list.